Novartis' Siponimod Emerges With Solid Safety, Skirts Gilenya's Heart Effects

Positive results from the Phase III EXPAND study of oral siponimod in secondary progressive multiple sclerosis, presented at ECTRIMS, lift Novartis ahead of Gilenya patent expiry and may be enough to support early approval.